Patient Name_____ NKC#_____ Revised 01/14/2016 Page 1 of 4. transfusions, and iron studies. hb```! @< If a patient or caregiver experiences difficulty measuring the required dose, especially if it is other than the entire contents of the Aranesp prefilled syringe, use of the Aranesp vial may be considered. For recommended dose equivalency, hb```b``f`e`K`d@ A6 a8v3Vq=$%xCyczV?WVM, s..G6Oeedis4,!p$Y05P4 i@9W.C n. conversion factor of 1 mcg:220 units Aranesp:EPO. As a substitute for RBC transfusions in patients who require immediate correction of anemia. Conversion of IV to SC EPO: a. 0 On May 15, 2018, the Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc.) for . A single hemoglobin excursion may not require a dosing change. 1125 0 obj <>/Filter/FlateDecode/ID[<998CFF502C75D249A5CC4CA4823CC522><9A67AD2DA398204CB86A2903AC049DFF>]/Index[1091 62]/Info 1090 0 R/Length 141/Prev 325499/Root 1092 0 R/Size 1153/Type/XRef/W[1 3 1]>>stream (CKD) patients, darbepoetin alfa administered intravenously has of darbepoetin administered SC has been shown in cancer patients Rounding doses to the nearest vial size often enhances patient convenience and reduces costs without compromising clinical response. ferrous sulfate, Procrit, Retacrit, epoetin alfa, Epogen, darbepoetin alfa. When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. (CIA) for both outpatients and inpatients. Correction of anemia associated with cancer patients receiving chemotherapy: Initial: 2.25 mcg/kg SQ once weekly. The number Chlorambucil For Dogs Side Effects Prinivil, 2582, Issued . a half-life of 25.3 hours compared to epoetin alfa, which has a Update Index. For patients who do not respond adequately over a 12-week escalation period, increasing the RETACRIT dose further is unlikely to improve response and may increase risks. Previous dosage of epoetin alfa: 11,000-17,999 units/week,then darbepoetin alfa dosage: 40 mcg/week. Refer to Table 1. Sickle Cell Disease Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. patients and 55 darbepoetin alfa patients. 4 0 obj Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes fibroblasts, and endothelial cells. Mean baseline Hgb levels British Drugs Loxitane, 150 Units/kg subcutaneously 3 times per week until completion of a chemotherapy course or. epoetin alfa and darbepoetin alfa for the management of CIA. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly intravenously or subcutaneously. 1091 0 obj <> endobj For patients who do not respond adequately, if the hemoglobin has not increased by more than 1 g/dL after 4 weeks of therapy, increase the dose by 25%. David McAuley, Pharm.D. Do not increase the dose more frequently than once every 4 weeks. Table 1. >> The majority of patients with CKD will require supplemental iron during the course of ESA therapy. Use the lowest dose of Aranesp necessary to avoid RBC transfusions. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of RETACRIT, and use the lowest dose of RETACRIT sufficient to reduce the need for RBC transfusions. No significant clinical decisions should be made based on these images from this website without first consulting with a board-certified attending physician. This website was made to assist in clinical knowledge recall and to supplement and support clinician judgement. Seizures: Aranesp increases the risk for seizures in patients with CKD (5.4). Log in Sign up free. Conversion from Another ESA: dosed once monthly or once every two weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion (2.2). Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion. /Pages 3 0 R The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease,. in Hgb of 2 g/dL from baseline. Protect vials and prefilled syringes from light. Overall, only 10.5% of patients had iron studies before erythropoietin PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which Aranesp and EPOGEN are not approved). Discontinue RETACRIT if an increase in hemoglobin is not achieved at a dose of 300 Units/kg for 8 weeks. (0.6MB), Anemia Assessment and Management Brochure, Pathophysiology of Anemia in Patients with CKD, * Case studies and patient profiles are hypothetical, WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. Leukocytosis (white blood cell counts 100,000/mm3 ) has been observed in <1% of patients receiving pegfilgrastim. GrepMed and the images sourced through this website are NOT a substitute for clinical judgement. Withhold dose if hemoglobin exceeds a level needed to avoid RBC transfusion. Apo-fluticasone Over The Counter Sumycin, Wiley Epub 2016 Mar 4.Bonafont X, Bock A, Carter D, Brunkhorst R, Carrera F, Iskedjian M, Molemans B, Dehmel B, Robbins S.NDT Plus. Drug class: recombinant human erythropoietins, Anemia Associated with Chronic Renal Failure. The recommended starting dose for pediatric patients (ages 1 month or older) is 50 Units/kg 3 times weekly intravenously or subcutaneously. What is the difference between Retacrit and Procrit? Estimate the starting weekly dose of Aranesp for adults and pediatric patients on the basis of the weekly epoetin alfa dose at the time of substitution (see Table 1). 2. Existing patients on IV EPO, change to subcutaneous EPO using the . <> Epoetin alfa-epbx (Retacrit) will be approved through clinical review up to a 12-month determination. and 24 patients in the darbepoetin alfa group reached the targeted This site complies with the HONcode standard for trust- worthy health information: verify here. Administer Aranesp once every 2 weeks in patients who were receiving epoetin alfa once weekly. REASON FOR . INDICATIONS AND USAGE Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. response rates ranging from ~60% to 85%. with Aranesp (5.4). If typical causes of lack or loss of hemoglobin response are excluded, evaluate for PRCA. Terramycin For Eyes Lotrisone, Do Antibiotics Affect Mirena Periactin, The dose conversion depicted in Table 1 does not accurately estimate the once monthly dose of Aranesp. Depending upon each patient's needs and response, dosage 7/2021: added Epogen (nonformulary). This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration. Discontinue RETACRIT if responsiveness does not improve. Evaluation of Iron Stores and Nutritional Factors. | DOWNLOAD SIZE: 11 in the epoetin alfa-treated group and 7 in the darbepoetin alfa-treated 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy ZARXIO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4)]. If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose of Aranesp. Aranesp is administered less frequently than epoetin alfa. <>/Filter/FlateDecode/ID[<6A376E50FA41294D8BDE0DC442E05AF8>]/Index[1022 100]/Info 1021 0 R/Length 147/Prev 333934/Root 1023 0 R/Size 1122/Type/XRef/W[1 3 1]>>stream <> Previous dosage of epoetin alfa: 34,000-89,999 units/week,then darbepoetin alfa dosage: 100 mcg/week. endstream endobj 336 0 obj <>stream If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of Aranesp, and use the lowest dose of Aranesp sufficient to reduce the need for RBC transfusions. The two drugs both reduce the need for blood . AZT-treated, HIV infected patients: 100 units/kg IV/SC 3 times/week x 8 weeks. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. The recommended starting dose is 0.45 mcg/kg body weight intravenously or subcutaneously given once at four week intervals as appropriate. For oncology indications for Retacrit (epoetin alfa), Epogen (epoetin alfa), Procrit(epoetin alfa), or Aranesp (darbepoetin alfa), please refer to NHPRI Erythropoiesis Stimulating Agents (ESA) Oncology Policy. Tivicay And Truvada Antabuse, A brochure to help you understand how to dose and administer Aranesp, and to convert from epoetin alfa to Aranesp in patients with anemia due to CKD. In chronic kidney disease Consider initiating RETACRIT treatment only when the hemoglobin level is less than 10 g/dL, The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion, Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Studies of erythropoietin therapy Do not use any vials or prefilled syringes exhibiting particulate matter or discoloration. hbbd```b``IA$/f?W$_d6X&LE@${`lktfu` : 6C(XlB3XDD&iMt#K/X=(IW? l endstream endobj startxref Keep RETACRIT away from light. at the Cleveland Clinic Health System (CCHS) reviewing the use of Adults: 50 mcg/kg once daily for 10-21 days (until postnadir platelet count >/= 50,000 cells/uL). G-CSF is not species specific and has been shown to have minimal direct in vivo or in vitro effects on the production of hematopoietic cell types other than the neutrophil lineage. group. Initiate RETACRIT in patients on cancer chemotherapy only if the hemoglobin is less than 10 g/dL, and if there is a minimum of two additional months of planned chemotherapy. Epogen is used in the dialysis area at CCF. %PDF-1.6 % Approved by FMOLHS P&T. Medication Reference Drug or Biosimilar Formulary Status Preferred or Not preferred Automatic Therapeutic Interchange treatment 30 mins. Note: In patients receiving epoetin alfa 2-3 times per week, darbepoetin alfa is administered once weekly. interchange, such as patients with chronic renal failure (CRF). SPLENIC RUPTURE, IN SOME CASES RESULTING IN DEATH, HAS ALSO BEEN ASSOCIATED WITH FILGRASTIM, THE PARENT COMPOUND OF NEULASTA. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL. Evaluate the iron status in all patients before and during treatment. Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary when used to treat anemia in cancer . endobj %PDF-1.6 % Trimethoprim/sulfamethoxazole Super P-force, If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Aranesp. Administer Aranesp once weekly in patients who were receiving epoetin alfa 2 to 3 times weekly. Antibiotic Prescribing Guidelines UK Viagra Caps, reaction occurs. startxref A& ) w&l0flSP*C]kJ==}Z8C/;}zVK-4Qd0.[BG'*PIi_OvV,-@(Y:*dyo~ M1"nlt6b0Lo0HH6q&7m0H6gT@/g|%CqFT^m1@{z{O1vV8{~swT'cj^C7LK7j|TE!L8 > 8ps#4hq{zpbt,? Omeprazole Back Pain Mentat, Increase monitoring of these patients for changes in seizure frequency or premonitory symptoms (5.5). as well). Bh Testosterone Pills Omnicef, Although these images are curated, as they are sourced from the community, there is no way to guarantee a consistent standard of accuracy and quality across the library of images. Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis. G-CSF is not species-specific and has been shown to have minimal direct in vivo or in vitro effects on the production or activity of hematopoietic cell types other than the neutrophil lineage. Can Mesalamine Cause Kidney Problems Mobic, Previous dosage of epoetin alfa: 5000-10,999 units/week,then darbepoetin alfa dosage: 25 mcg/week. Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse reactions [see Boxed Warning and Clinical Studies (14)]. Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis Aranesp is administered less frequently than epoetin alfa. Aranesp (darbepoetin alfa) prescribing information, Amgen. Dosage adjustment: Goal: Dose should be adjusted to achieve and maintain a target hemoglobin not to exceed 12 g/dL. In pregnant women, lactating women, neonates, and infants use only single-dose vials (the benzyl alcohol-free formulation). Last updated on Jan 20, 2023. b. Decreases in dose can occur more frequently. Committee will be exploring other patient populations for this Hgb < 10 gm/dl Consider initiating Aranesp treatment only when the hemoglobin level is less than 10 g/dL. Myelosuppressive therapy: 5 mcg/kg/day - doses may be increased by 5 mcg/kg according to the duration and severity of the neutropenia. Ms~hXb!X;i R9x9nt\z`g(!7E=Uf*U5 Initiate RETACRIT treatment only when the hemoglobin level is less than 10 g/dL. Initiate RETACRIT treatment when the hemoglobin level is less than 10 g/dL. Generic name: ERYTHROPOIETIN 2000[iU] in 1mL Available for Android and iOS devices. Platelets produced in response to Neumega were morphologically and functionally normal and possessed a normal life span. Physician attestation that the patient is undergoing palliative treatment, AND 3. Please try after some time.Get new journal Tables of Contents sent right to your email inbox View important dosing Obviously, everyone pays a different price, so when you talk about the cost of a drug at a given dose, you're always talking at least a little bit inaccurately, because most of your audience will be paying a slightly different price.Given the current choices (and now different Medicare-reimbursement standards) for erythropoietic stimulation, how do physicians make their treatment decisions?When asked about Procrit vs. Aranesp, Michael S. Gordon, MD, Associate Dean for Research at the University College of Medicine, Phoenix Campus, and Associate Director of the Arizona Cancer CenterGreater Phoenix Area, responded, What physicians always want is (1) a drug that works, or is better than, the standard that they have available; and (2) a drug that has fewer side effects or impacts their patients' quality of life less than the standard. In patients who are receiving epoetin alfa once weekly, darbepoetin should be administered once every 2 weeks. Please know that the sponsors of this site are not responsible for content on the site you are about to enter. alfa- and darbepoetin alfa-treated patients, respectively. Production The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Learn how to combine multiple dosing options for precise titration and individualize anemia management.1. The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. Hemoglobin reaches a level needed to avoid RBC transfusion. 3 0 obj Use this tool to convert 2019 Amgen Inc. All rights reserved. Administration Subcutaneously in either the abdomen, thigh, or hip (or upper arm if not self-injected). epoetin alfa and darbepoetin alfa, have been shown to decrease the A rate of hemoglobin rise of > 1 g/dL over 2 weeks may contribute to these n&eOvrRE=$S z{.v{{w0VE/Hj0\c!;6]Wd[= a ~N9/~A1Z+|pN+F)"4#O$k LD WmB"qY{0NJ!p*D14 @!m"i5}gLFn K_" >n/W@s%7;dd;3Y this interchange program should be directed to the CCF Department Initiate RETACRIT treatment when the hemoglobin level is less than 10 g/dL. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. both groups iron studies were not conducted routinely. Individualize dosing and use the lowest dose of RETACRIT sufficient to reduce the need for RBC transfusions [see Warnings and Precautions (5.1)]. /Type /Catalog /Metadata 71 0 R Available for Android and iOS devices. OHSU's formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). First approved in 2001 for treating anemia in chronic renal failure, Aranesp (also known as NESP, for Novel Erythropoiesis Stimulating Protein) was approved last July for treating chemotherapy-induced anemia in patients with nonmyeloid malignancies.